Duan Bin
Mary & Dick Holland Regenerative Medicine Program, Division of Cardiology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Department of Surgery, University of Nebraska Medical Center, Omaha, NE 68198, USA.
J Transl Int Med. 2020 May 9;8(1):20-25. doi: 10.2478/jtim-2020-0004. eCollection 2020 Mar.
Ischemic heart disease (IHD) is one of the most common cardiovascular diseases and is the leading cause of death worldwide. Stem cell therapy is a promising strategy to promote cardiac regeneration and myocardial function recovery. Recently, the generation of human induced pluripotent cells (hiPSCs) and their differentiation into cardiomyocytes and vascular cells offer an unprecedented opportunity for the IHD treatment. This review briefly summarizes hiPSCs and their differentiation, and presents the recent advances in hiPSC injection, engineered cardiac patch fabrication, and the application of hiPSC derived extracellular vesicle. Current challenges and further perspectives are also discussed to understand current risks and concerns, identify potential solutions, and direct future clinical trials and applications.
缺血性心脏病（IHD）是最常见的心血管疾病之一，也是全球主要的死亡原因。干细胞疗法是促进心脏再生和心肌功能恢复的一种有前景的策略。最近，人类诱导多能干细胞（hiPSC）的产生及其向心肌细胞和血管细胞的分化为缺血性心脏病的治疗提供了前所未有的机会。本文简要总结了hiPSC及其分化，并介绍了hiPSC注射、工程心脏补片制造以及hiPSC衍生细胞外囊泡应用方面的最新进展。还讨论了当前的挑战和进一步的前景，以了解当前的风险和问题，确定潜在的解决方案，并指导未来的临床试验和应用。
